Recombinant Human RAF1 Protein

重组人RAF1蛋白 | 重组人Raf-1原癌基因，丝氨酸/苏氨酸激酶蛋白

cRaf | c-Raf | c-Raf-1 | CRAFraf proto-oncogene serine/threonine protein kinase | EC 2.7.11 | EC 2.7.11.1 | NS5 | Proto-oncogene c-RAF | RAF proto-oncogene serine/threonine-protein kinase | RAF | Raf1 | Raf-1 | Raf-1Oncogene RAF1 | v-raf-1 murine leukemia

rp217603-10μg

10μg

无载体

≥95%(SDS-PAGE)

Involved in the transduction of mitogenic signals from the cell membrane to the nucleus. Part of the Ras-dependent signaling pathway from receptors to the nucleus. Protects cells from apoptosis mediated by STK3. Post-translational: Phosphorylation at Thr-269, Ser-338, Tyr-341, Thr-491 and Ser-494 results in its activation. Phosphorylation at Ser-29, Ser-43, Ser-289, Ser-296, Ser-301 and Ser-642 by MAPK1/ERK2 results in its inactivation. Phosphorylation at Ser-259 induces the interaction with YWHAZ and inactivates kinase activity. Dephosphorylation of Ser-259 by the SHOC2-MRAS-PP1c (SMP) complex consisting of SHOC2, GTP-bound M-Ras/MRAS and the catalytic subunit of protein phosphatase 1 (PPP1CA, PPP1CB or PPP1CC); this relieves inactivation and stimulates kinase activity (PubMed:35768504, PubMed:35831509, PubMed:35830882). Phosphorylation at Ser-338 by PAK1 and PAK5 and Ser-339 by PAK1 is required for its mitochondrial localization. Phosphorylation at Ser-621 in response to growth factor treatment stabilizes the protein, possibly by preventing proteasomal degradation. Phosphorylation at Ser-289, Ser-296, Ser-301, Ser-338 and Ser-621 are somehow linked to the methylation potential of cells. Treatment of cells with HGF in the presence of the methylation inhibitor 5'-methylthioadenosine (MTA) results in increased phosphorylation at Ser-338 and Ser-621 and decreased phosphorylation at Ser-296, Ser-301 and Ser-338. Dephosphorylation at Ser-338 by PPP5C results in an activity decrease. Methylated at Arg-563 in response to EGF treatment. This modification leads to destabilization of the protein, possibly through proteasomal degradation.

重组表达

19.1 kDa

N-His

19.6 kDa, under reducing conditions; 19.6 kDa, under non-reducing conditions.

E. coli Accession #: P04049 | E. coli

<1.0 EU/μg

人(Human)

189-353 aa

MHHHHHHNIRQLLLFPNSTIGDSGVPALPSLTMRRMRESVSRMPVSSQHRYSTPHAFTFNTSSPSSEGSLSQRQRSTSTPNVHMVSTTLPVDSRMIEDAIRSHSESASPSALSSSPNNLSPTGWSQPKTPVPAQRERAPVSGTQEKNKIRPRGQRDSSYYWEIEASEVMLST

No

Yes